Linked Life Data

18549330

Source:http://linkedlifedata.com/resource/pubmed/id/18549330

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2008-6-13
pubmed:abstractText
The advent of biologic therapy for Crohn's disease has revolutionized our approach to disease management and redefined our goals. Infliximab (Remicade), an intravenously delivered murine-chimeric monoclonal antibody against TNF-alpha was released in 1998 and shown to have significant benefits in patients with refractory luminal and fistulizing Crohn's disease. Since then other anti-TNF strategies have undergone investigation with variable results. Adalimumab (Humira), a self administered, subcutaneous, fully human monoclonal antibody against TNF-alpha represents the next generation of therapy. It has demonstrated efficacy for induction and maintenance of remission in patients with moderate-to-severe Crohn's in three large double-blind, placebo-controlled, randomized trials. In addition it has demonstrated steroid-sparing properties and the ability to reduce hospitalizations and improve quality of life. It is anticipated, given its clinical efficacy, its fully human nature, and the convenience of self administration that it will have a significant effect on the management of Crohn's disease.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1744-7682
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1011-9
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Adalimumab for the treatment of Crohn's disease.
pubmed:affiliation
University of Calgary Medical Clinics, The University of Calgary, Inflammatory Bowel Disease Clinic, 3330 Hospital Drive NW, Room 127, Calgary, Alberta, Canada.
pubmed:publicationType
Journal Article, Review